Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06344650` - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting	`NCT02092129` - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.	N/A
Completed	`NCT02012127` - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting	`NCT01265121` - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.	N/A
Terminated	`NCT00765323` - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly	Phase 3
Completed	`NCT00500227` - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed	`NCT00531908` - Physiopathology of Sodium Retention in Acromegaly	N/A
Completed	`NCT01278342` - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients	Phase 4
Active, not recruiting	`NCT01809808` - A Prospective Study of Outcome After Therapy for Acromegaly
Completed	`NCT00145405` - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction	Phase 4
Completed	`NCT00210457` - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients	Phase 3
Recruiting	`NCT05401084` - Diet in the Management of Acromegaly	N/A
Recruiting	`NCT00005100` - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly	N/A
Completed	`NCT00521300` - Preoperative Octreotide Treatment of Acromegaly	Phase 4
Completed	`NCT03548415` - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands	Phase 2
Not yet recruiting	`NCT04066569` - Reproducibility and Utility of OGTT in Acromegaly	N/A
Not yet recruiting	`NCT05298891` - Hypoproteic Diet in Acromegaly	N/A
Recruiting	`NCT04520646` - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy	N/A
Not yet recruiting	`NCT04529356` - The TMS Treatment for Postoperative Headache in GH Tumor	N/A
Active, not recruiting	`NCT03252353` - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly	Phase 3

NCT number	NCT02807233
Study type	Observational
Source	Ipsen
Contact
Status	Completed
Phase
Start date	July 2016
Completion date	September 2017

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects — SOMACROL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms